Pharmacy- Page 19

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020

Pharmacy

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results

by The FINANCIAL

November 16, 2020

2 mins read

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

The FINANCIAL — Metagenomi, a next generation gene editing company launched by

by The FINANCIAL

November 12, 2020

1 min read

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The FINANCIAL — On the occasion of the World Health Assembly, the world’s

by The FINANCIAL

November 12, 2020

1 min read

Pharmacy

U.S. FDA Approves Expanded Labeling for Epclusa

The FINANCIAL -- Gilead Sciences, Inc. on August 1 announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with

by The FINANCIAL

August 2, 2017

1 min read

Pharmacy

Amgen Submits Supplemental Biologics License Application For Prolia

The FINANCIAL -- Amgen on July 31 announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP).

by The FINANCIAL

August 1, 2017

1 min read

Pharmacy

Sanofi Q2 Profit Declines, Sales Rise

The FINANCIAL -- Sanofi Chief Executive Officer, Olivier Brandicourt, commented:

by The FINANCIAL

July 31, 2017

15 mins read

Pharmacy

AbbVie’s profit beats on Humira, Imbruvica demand

The FINANCIAL -- AbbVie announced financial results for the second quarter ended June 30, 2017.

by The FINANCIAL

July 28, 2017

4 mins read

Pharmacy

Astellas Reports First Quarter FY2017 Financial Results

The FINANCIAL -- Astellas Pharma Inc. on July 28 announced the financial results for the first quarter of fiscal year 2017, ending March 31, 2018.

by The FINANCIAL

July 28, 2017

2 mins read

Pharmacy

European Commission Grants Marketing Authorization for Gilead’s Vosevi

The FINANCIAL -- Gilead Sciences, Inc. on July 28 announced that the European Commission has granted marketing authorization for Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus

by The FINANCIAL

July 28, 2017

4 mins read

Pharmacy

Bristol-Myers Squibb Reports Second Quarter Financial Results

The FINANCIAL -- Bristol-Myers Squibb Company on July 27 reported results for the second quarter of 2017 which were highlighted by strong sales for key products Opdivo and Eliquis and regulatory approvals for Opdivo, the Daklinza and Sunvepra regimen and Orencia.

by The FINANCIAL

July 28, 2017

7 mins read

Pharmacy

Roche reports strong performance in the first half of 2017

The FINANCIAL -- Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful

by The FINANCIAL

July 28, 2017

6 mins read

Pharmacy

Merck & Co Inc. Q2 Earnings Rise 7%

The FINANCIAL -- Merck, known as MSD outside the United States and Canada, on July 28 announced financial results for the second quarter of 2017.

by The FINANCIAL

July 28, 2017

8 mins read

Pharmacy

Bayer: Group performance matches prior year despite declines at Crop Science

The FINANCIAL -- The Bayer Group’s performance in the second quarter of 2017 matched the prior-year period, despite the company registering declines at Crop Science.

by The FINANCIAL

July 27, 2017

9 mins read